Orexigen conquers French objections to obesity drug with EU approval
This article was originally published in Scrip
Orexigen has overcome objections from France to receive European Commission approval for its obesity product Mysimba (naltrexone HCl / bupropion HCl prolonged release) in all 28 EU member states.
You may also be interested in...
Consilient, which markets Orexigen’s obesity drug Mysimba in the UK and Ireland, says it is “extremely disappointed” by NICE’s decision to reject the product for use on the NHS. NICE said it had concerns over the drug’s long-term effectiveness and its ability to offer value to the health service.
Orexigen has a tough climb ahead as it sets out without a US partner to boost sales for its obesity drug Contrave with the goal of profitability by 2019, but it appears that doctors, patients and payers are becoming more open to pharmaceutical treatment.
Sanofi/Regeneron’s anti-PD-1 product Libtayo may be late to the NSCLC party but strong data from EMPOWER-Lung 1 suggest it could gain traction in the space, especially in patients with high PD-L1 expression levels.